DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products.
$10.45+6.63%
报价 2026-11-06
市值
$250M
EV
$196.9M
PE (TTM)
–
预期 PE
–
52 周区间距高点 -57.4%
$8.87$24.54
筛选结果
pipeline · 2026-11-06Filter✗ 高增长✗ Cheap✗ GARP
excluded industry: Biotechnology
研究结论
还没有研究记录。先生成 L2 基本面报告（约 1–3 分钟），结论会显示在这里。
去生成基本面报告 →历史股价
加载中…
事件
0 条 · 随区间与图例筛选该区间内无事件。
同行对比
同行业市值相近 · Biotechnology| 公司 | 市值 | 今日 | 预期营收增速 | 毛利率 | PE | EV/EBITDA | P/FCF | 池 |
|---|---|---|---|---|---|---|---|---|
| DBVTDBV Technologies S.A. | $250M | +6.6% | – | -110.7% | – | – | – | |
| VOGXVogenx Inc. | $259.2M | -4.3% | – | – | – | – | – | |
| LCTXLineage Cell Therapeutics, Inc. | $258M | +3.8% | – | – | – | – | – | |
| CAMPCAMP4 Therapeutics Corporation | $254.8M | +9.1% | +63.9% | 77.8% | – | – | – | |
| SCTXScribe Therapeutics Inc. | $254.1M | +1.4% | – | – | – | – | – | |
| BCYCBicycle Therapeutics plc | $253M | +3.7% | – | 100% | – | – | – | |
| LRMRLarimar Therapeutics, Inc. | $248.3M | +3.0% | – | 0% | – | – | – | |
| EVMNFunctional Brands, Inc. Common Stock | $241.3M | +4.4% | -48.5% | 100% | – | – | – | |
| AMRNAmarin Corporation plc | $240.1M | +0.3% | – | 65.7% | – | – | – | |
| 同行中位数 | – | – | +7.7% | 77.8% | – | – | – |
研究全文
L2 基本面 memo
尚无基本面 memo
点击「生成基本面报告」——基于最新 filings、电话会纪要与分析师共识生成 L2 memo。
财务报表
暂无季度数据（首次研究运行后填充）。